Cisplatin is a preferred treatment for a wide range of cancers, including breast, head and neck, lung, ovary, and more. However, its side effects — particularly nephrotoxicity — can be severe. Kidney ...
Between January 2021 and March 2022, 66 patients were included. The OR was 48.5% (95% CI, 36 to 61), with seven (10.61%) patients experiencing complete response. The median DoR was 9.2 months (95% CI, ...
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable ...
No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. In this phase 3, multinational, ...
Please provide your email address to receive an email when new articles are posted on . The cisplatin shortage forced many patients with head and neck cancer to use alternative therapies. Treatment ...
In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback